Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
March 27, 2017
RegMed Investors’ (RMi) mid-day analysis, retracing
March 13, 2017
Fate Therapeutics (FATE) FDA clears an IND for FATE-NK100
March 10, 2017
Fibrocell (FCSC) 1 for 3 reverse stock split
February 9, 2017
BioTime (NYSEMKT: BTX) Proposes offering of 6.48 M shares at $2.70
February 9, 2017
RegMed Investors’ (RMi) mid-day analysis, momentum has a short fuse
February 7, 2017
RegMed Investors’ (RMi) mid-day analysis, a fast walk to the upside
January 31, 2017
Bellicum Pharmaceutics (BLCM) new CEO
January 28, 2017
Can you afford to miss the insider view
January 26, 2017
RegMed Investors’ (RMi) mid-day analysis, pricing is jockeying
January 24, 2017
RegMed Investors’ (RMi) mid-day analysis, slam, bam and no thank you
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors